Everads specializes in developing suprachoroidal delivery technology for ocular gene therapy, as self-described in various announcements regarding their innovations and clinical trials.

Everads

Everads Therapy Ltd | 290 followers on LinkedIn. Optimizing Treatment of Retinal Disease by Leveraging Novel Delivery Technology | Everads Therapy is an early-stage life sciences company developing the next generation of retinal treatment delivery technologies. With the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases, Everads&#39; delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Established in 2017, Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel.

Hagay Drori

Executive Chairman at Everads Therapy and CEO at Moebius Medical Ltd.

Moshe Weinstein

Drug delivery design expert | Medical devices entrepreneur

Lior Raday

Clinical Operations Expert

Adi Bigger Hoggeg

Everads Therapy Ltd

💫 Everads is excited to announce that it was selected as the top startup at the Eye and Beyond II conference hosted by the Ophthalmology Division of the Rabin Medical Center. Congratulations to Keren Mano-Tamir (M.D / MBA) for this great achievement! 👏 #ophthalmology #suprachoroidal #drugdelivery #genetherapy #everads

Everads is excited to have initial clinical data using our suprachoroidal delivery technology presented at EURETINA. Congratulations to Dr. Y Barak, Head of Retina and Rambam Medical Center, for this achievement! #opthalmology #suprachoroidal #drugdelivery #genetherapy https://lnkd.in/dDdGz7E8

I am excited to share that Everads will be leading the Suprachoroidal Delivery Workshop at the gene therapy for ophthalmic disorders summit. See you there!

Everads is happy to share that the ability of our suprachoroidal delivery technology to delivery AAV-based gene therapy to the back of the eye is being presented today by Dr. Yoreh Barak of Rambam Medical Center at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. For those at ARVO, please come by poster B0029 3:30-5:15pm! #opthalmology #suprachoroidal #drugdelivery #genetherapy

Our CEO Moshe Weinstein will be sharing updates regarding Everads and our suprachoroidal delivery platform this week at 2nd Next Generation Ophthalmic Drug Delivery conference. We look forward to seeing you there!

EVER

COM:EVERADS-THERAPY

Everads